Abstract
The number of approvals for new drugs and biologics has fallen steadily in
recent years, despite increasing R&D expenditure. Cost effective and
innovative approaches to drug discovery and development have therefore become
particularly important to ensure shareholder value. Improvements to the lead
generation process are a key initiative for company' s aiming to avoid
expensive compound failures in the latter stages of the drug discovery
process. ‘Accelerating Lead Generation: Emerging technologies and
strategies' is a new report published by Business Insights that provides an
in-depth examination of state-of-the-art technologies for lead generation.
This report assesses the potential of new and emerging technologies for
improving the quality of drug candidates entering clinical research, and
reviews the benefits associated with different approaches to lead generation,
including high throughput screening, fragment based drug discovery and virtual
screening. The lead generation strategies adopted by leading pharma companies
are evaluated to provide strategic recommendations for success, and the trends
that are shaping the future acceleration of lead generation are identified.
| 
View Cart
